Encouraging AGM and M3 updates
Destiny’s recent announcement on the progress on its lead asset NTCD-M3 maintains the momentum that has built since the acquisition of M3 in 2020. In addition, while the AGM narrative did not promise a licensing transaction on either of Destiny’s Phase 3-ready assets, the timelines for partnerships in 2021 and the Phase 3 studies starting in 2022 remain intact.Destiny also welcomes the recent G7 Health Ministers’ Meeting communique on 4 June and its strong message highlighting the global threat of the “silent pandemic” of Antimicrobial Resistance (AMR) and the urgent need for the development of new treatments.
Although Destiny described NTCD-M3 as its lead asset because the Phase 3 protocol has already been agreed with the FDA, choosing between these two assets is like choosing between your children. Both are viable assets and both could easily be partnered in 2021.
Destiny’s CEO presentation at its AGM reinforced the additional attributes of a low cost for a single strain product, the convenience and shelf-life advantages of a solid dose oral format. In contrast, Destiny’s M3 product does not have the gene to produce toxin so is firstly a safer option, and additionally an easier product for regulators to assess since it does not need testing for toxin production.
Our forecasts and fair value of Destiny Pharma at £200.2m or 335p / share are unchanged, although there is the potential for more than one partnering transaction in 2021. We have only assumed one such deal and would remind investors that licensing transactions can include an equity investment component by the licensee, usually at a premium to market price.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.